clarithromycin has been researched along with 3'-hydroxy-5'-(4-isobutylpiperazinyl)benzoxazinorifamycin in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 14 (82.35) | 18.2507 |
| 2000's | 2 (11.76) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Ding, C; Doyle, T; Duncan, L; Ebright, RH; He, S; Lin, W; Liu, Y; Lynch, AS; Ma, Z; Molodtsov, V; Nguyen, P; Pulse, M; Robertson, GT; Wang, H; Weiss, WJ; Xu, X; Yuan, Y; Zhuang, Z | 1 |
| Dekio, S; Hidaka, T; Kawahara, S; Saito, H; Sato, K; Tomioka, H | 1 |
| Barbara-Burnham, L; Bermudez, LE; Inderlied, CB; Wu, M; Young, LS | 1 |
| Bermudez, LE; Inderlied, CB; Kolonoski, P; Young, LS | 1 |
| Gidoh, M; Saito, H | 1 |
| Amitani, R; Kuze, F; Murayama, T; Suzuki, K; Tanaka, E; Yamamoto, T | 1 |
| Grosset, J; Ji, B; Lounis, N; Truffot-Pernot, C | 1 |
| Akaki, T; Sato, K; Tomioka, H | 2 |
| Akaki, T; Kawahara, S; Sato, K; Shimizu, T; Tomioka, H | 1 |
| Amitani, R; Hashimoto, T; Kuze, F; Matsumoto, H; Suzuki, K; Tanaka, E; Tsuyuguchi, K; Yamamoto, T | 1 |
| Sato, K; Tomioka, H | 2 |
| Akaki, T; Ogasawara, K; Sato, K; Tomioka, H | 1 |
| Gidoh, M; Hidaka, T; Kobayashi, K; Kwon, HH; Murakami, K; Saito, H | 1 |
| Akaki, T; Kawahara, S; Sato, K; Tomioka, H | 1 |
| Sano, C; Sano, K; Sato, K; Shimizu, T; Tomioka, H | 1 |
2 review(s) available for clarithromycin and 3'-hydroxy-5'-(4-isobutylpiperazinyl)benzoxazinorifamycin
| Article | Year |
|---|---|
[Present status of studies on antileprosy drugs].
Topics: Animals; Clarithromycin; Dapsone; Drug Therapy, Combination; Humans; Immunologic Factors; Leprostatic Agents; Minocycline; Prothionamide; Quinolones; Rifampin; Rifamycins; Thalidomide | 1995 |
[In vitro antimicrobial activities of quinolones, rifamycins and macrolides against Mycobacterium tuberculosis and M.avium complex: attempt to establish new assay methods which accurately reflect therapeutic effects of test agents in vivo].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitubercular; Cells, Cultured; Clarithromycin; Drug Resistance, Microbial; Humans; Microbial Sensitivity Tests; Mycobacterium avium Complex; Mycobacterium tuberculosis; Ofloxacin; Rifamycins | 1999 |
1 trial(s) available for clarithromycin and 3'-hydroxy-5'-(4-isobutylpiperazinyl)benzoxazinorifamycin
| Article | Year |
|---|---|
Activity of KRM 1648 or rifabutin alone or in combination with clarithromycin against Mycobacterium avium complex in human alveolar macrophages.
Topics: Adult; Anti-Bacterial Agents; Antibiotics, Antitubercular; Bronchoalveolar Lavage; Cells, Cultured; Clarithromycin; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; L-Lactate Dehydrogenase; Macrophages, Alveolar; Male; Microbial Sensitivity Tests; Middle Aged; Mycobacterium avium Complex; Reference Values; Rifabutin; Rifamycins; Smoking | 1997 |
14 other study(ies) available for clarithromycin and 3'-hydroxy-5'-(4-isobutylpiperazinyl)benzoxazinorifamycin
| Article | Year |
|---|---|
Design, Synthesis, and Characterization of TNP-2198, a Dual-Targeted Rifamycin-Nitroimidazole Conjugate with Potent Activity against Microaerophilic and Anaerobic Bacterial Pathogens.
Topics: Anaerobiosis; DNA-Directed RNA Polymerases; Helicobacter Infections; Helicobacter pylori; Humans; Nitroimidazoles; Rifamycins | 2022 |
Therapeutic effect of KRM-1648 with various antimicrobials against Mycobacterium avium complex infection in mice.
Topics: Animals; Antitubercular Agents; Clarithromycin; Clofazimine; Drug Synergism; Drug Therapy, Combination; Ethambutol; Fluoroquinolones; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Microbial Sensitivity Tests; Mycobacterium avium-intracellulare Infection; Ofloxacin; Quinolones; Rifamycins; Streptomycin | 1995 |
Activities of the benzoxazinorifamycin KRM 1648 and ethambutol against Mycobacterium avium complex in vitro and in macrophages.
Topics: Antibiotics, Antitubercular; Cell Line; Clarithromycin; Ethambutol; Humans; Macrophages; Microbial Sensitivity Tests; Mycobacterium avium Complex; Rifamycins | 1994 |
Activity of KRM 1648 alone or in combination with ethambutol or clarithromycin against Mycobacterium avium in beige mouse model of disseminated infection.
Topics: Animals; Antibiotics, Antitubercular; Clarithromycin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ethambutol; Female; Mice; Mice, Inbred C57BL; Mycobacterium avium; Rifamycins; Tuberculosis | 1994 |
Activity of KRM-1648 alone or in combination with both ethambutol and kanamycin or clarithromycin against Mycobacterium intracellulare infections in beige mice.
Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antitubercular; Antitubercular Agents; Clarithromycin; Colony Count, Microbial; Drug Combinations; Drug Therapy, Combination; Ethambutol; Female; Kanamycin; Lung; Male; Mice; Mycobacterium avium Complex; Rifampin; Rifamycins; Spleen; Tuberculosis | 1996 |
How effective is KRM-1648 in treatment of disseminated Mycobacterium avium complex infections in beige mice?
Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antitubercular; Clarithromycin; Drug Combinations; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Kanamycin; Lung; Male; Mice; Microbial Sensitivity Tests; Mycobacterium avium Complex; Rifamycins; Spleen; Tuberculosis | 1996 |
[Anti-Mycobacterium avium complex activities of KRM-1648, clarithromycin and levofloxacin in 7HSF medium at peak or average blood concentrations after their oral administration of clinical dosages].
Topics: Administration, Oral; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitubercular; Clarithromycin; Culture Media; Humans; Levofloxacin; Mycobacterium avium Complex; Ofloxacin; Rifamycins | 1997 |
[In vivo activities of benzoxazinorifamycin KRM-1648, clarithromycin, and levofloxacin, or combination of KRM-1648 with diclofenac sodium against Mycobacterium avium infection induced in mice].
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibiotics, Antitubercular; Clarithromycin; Diclofenac; Drug Therapy, Combination; Female; Levofloxacin; Mice; Mice, Inbred BALB C; Mycobacterium avium; Ofloxacin; Rifamycins; Tuberculosis | 1997 |
Antimicrobial activities of benzoxazinorifamycin KRM-1648, clarithromycin and levofloxacin against intracellular Mycobacterium avium complex phagocytosed by murine peritoneal macrophages.
Topics: Animals; Anti-Bacterial Agents; Clarithromycin; Female; Levofloxacin; Lung; Macrophages, Peritoneal; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mycobacterium avium; Ofloxacin; Phagocytosis; Rifamycins; Tuberculosis | 1998 |
Antimicrobial activities of benzoxazinorifamycin (KRM-1648) and clarithromycin against Mycobacterium avium-intracellulare complex within murine peritoneal macrophages, human macrophage-like cells and human alveolar epithelial cells.
Topics: Animals; Anti-Bacterial Agents; Cell Line; Clarithromycin; Epithelial Cells; Female; Humans; Macrophages; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mycobacterium avium Complex; Pulmonary Alveoli; Rifamycins | 1999 |
[MICs and MBCs of levofloxacin, clarithromycin, and KRM-1648 for Mycobacterium tuberculosis and M. avium complex residing in MONO-MAC-6 human macrophage-like cell and A-549 human type II alveolar epithelial cell lines].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitubercular; Cells, Cultured; Clarithromycin; Humans; Levofloxacin; Macrophages; Microbial Sensitivity Tests; Mycobacterium avium Complex; Mycobacterium tuberculosis; Ofloxacin; Pulmonary Alveoli; Rifamycins | 1999 |
[Chemoprophylaxis against Mycobacterium avium complex infection induced in mice].
Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antitubercular; Clarithromycin; Female; Mice; Mycobacterium avium-intracellulare Infection; Rifabutin; Rifamycins | 1999 |
Antimicrobial activities of levofloxacin, clarithromycin, and KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium complex replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines.
Topics: Anti-Bacterial Agents; Cell Line; Clarithromycin; Epithelial Cells; Humans; Levofloxacin; Macrophages; Microbial Sensitivity Tests; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Mycobacterium tuberculosis; Ofloxacin; Pulmonary Alveoli; Rifamycins; Tuberculosis | 2000 |
Intramacrophage passage of Mycobacterium tuberculosis and M. avium complex alters the drug susceptibilities of the organisms as determined by intracellular susceptibility testing using macrophages and type II alveolar epithelial cells.
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Cells, Cultured; Clarithromycin; Epithelial Cells; Humans; Levofloxacin; Macrophages; Microbial Sensitivity Tests; Mycobacterium avium Complex; Mycobacterium tuberculosis; Ofloxacin; Rifamycins | 2002 |